Feb 8 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO :
* Announces preliminary topline data from its open label aurion study in lupus
nephritis
* -100% of patients receiving multi-target therapy with voclosporin achieved at
least a 25% reduction of proteinuria at 8 weeks
* Source text for Eikon Further company coverage AUP.TO